Blog Tool

Sensydia Completes Fifth Study for Heart-Sound AI

Completion of this 50-subject study is a key milestone on the path to delivering the first device for non-invasive and accurate...

Sensydia secures $3M NIH grant to advance AI-based cardiac assessment platform

NIH STTR Fast-Track grant helps propel Sensydia's non-invasive CPS platform building on recent funding round Los Angeles, CA – June 5,...

Sensydia raises $8M round to advance breakthrough CPS cardiac assessment platform

Sensydia continues to push the boundaries of AI in heart function assessment Los Angeles, CA – May 9, 2023 – Non-invasive cardiac...

Sensydia Achieves Study Target for Heart-Sound AI

Completion of enrollment for this 225-subject study is a key milestone on the path to delivering the first device for non-invasive and...

Sensydia Receives FDA Breakthrough Device Designation for CPS Non-Invasive Cardiac Monitoring Device

External device uses heart sound and AI to deliver rapid cardiac function assessments via tablet to expand hemodynamic evaluation beyond...

Sensydia Appoints Anthony Arnold as President and Chief Executive Officer

Los Angeles – October 1, 2019 – Sensydia Corporation, an innovator in rapid, non-invasive measurement of critical cardiac function,...

FDA Clears Sensydia’s Cardiac Performance System

The Sensydia Cardiac Performance System (CPS) is the first patient-worn system to provide Ejection Fraction information to clinicians for...

Sensydia Completes Series B Financing

Sensydia Corporation announces that it has complete a Series B financing. The financing was led by Colle Capital and included all Series...

Sensydia Completes Series A Financing

Sensydia Corporation has completed its first round of financing which will be used to develop its patent pending technology to detect...